Genotypes and Phenotypes in Pediatric SIRS and Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this investigation is to longitudinally quantify host gene expression and serum proteins in children with infectious and non-infectious SIRS. The investigators hypothesize that children with non-infectious SIRS, with bacterial infection associated SIRS, or with viral infection associated SIRS will exhibit distinct patterns of host gene expression and serum proteins. The investigators further hypothesize that it should be possible to discover sets of mRNA or protein biomarkers that will permit unambiguous diagnosis of non-infectious SIRS, SIRS associated with bacterial infection, and SIRS associated with viral infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Biologic Validation of Biomarkers of Progressive NEC & Sepsis

NCT00588718

Necrotizing Enterocolitis

UNKNOWN

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis

NCT01294865

Neonatal Sepsis

UNKNOWN

The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19

NCT05619640

SARS CoV 2 Infection Alveolar; Injury Children +1 more

COMPLETED

Rapid Diagnostic Test for Septic Arthritis

NCT04460144

Juvenile Idiopathic Arthritis Arthritis, Septic Arthritis, Unspecified

COMPLETED

GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

NCT03769844

Pediatric Sepsis-induced MODS

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will undertake a proof-of-concept, pilot, prospective, observational trial that aims to recruit \~90 children from the Seattle Children's Hospital Pediatric Intensive Care Unit (PICU) and Cardiac Intensive Care Unit (CICU). The study will plan to recruit 30 children who are scheduled for surgery to repair congenital cardiac malformations, 15 - 25 immunocompetent children with culture positive sepsis, and 15 - 25 immunocompromised children with culture positive sepsis, and 30-40 children who are polymerase chain reaction (PCR) positive for viral respiratory pathogens (RSV, influenza, parainfluenza, rhinovirus, etc), and who meet the eligibility criteria. In total, accounting for culture negative bacterial sepsis (estimated 40%), the investigators plan to enroll 50 children with sepsis, 30-40 with viral sepsis, and 20 children undergoing surgery for congenital heart disease.

Demographic data will be collected at the time of ICU admission. Illness severity will be quantified by PRISM III and day 1 PELOD scores. Additional measures of sepsis severity will include oxygenation index, saturation index and duration of mechanical ventilation, vasoactive inotropic score and duration of vasoactive-inotropic support and highest serum creatinine on day 1. Resource utilization will be measured as PICU and hospital duration of stay.

For all children enrolled in the study, blood samples will be obtained on study days 1, 2 and 3. For children with sepsis, if cultures remain sterile or PCR negative, no additional research blood samples will be obtained. For children with sepsis and a positive culture or positive PCR by study day 3, additional blood samples will be obtained on the day of PICU discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Inflammatory Response Syndrome (SIRS) Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

INSI

Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for \~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).

No interventions assigned to this group

CSSS

Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).

No interventions assigned to this group

Viral

The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion \& exclusion criteria (see Eligibility section below).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admission to the CICU AND
* Age \~1-18 years AND
* Weight exceeding 10 kg
* Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
* Status post open heart surgery requiring cardiopulmonary bypass AND
* Parents speak English AND
* Not previously enrolled in the GAPPSS investigation

* Admitted to the PICU AND
* Age newborn (\>38 weeks EGA)-18 years AND
* Weight equal to or greater than 4 kg AND
* Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
* At least one organ dysfunction (severe sepsis) AND
* Parents speak English AND
* SIRS (systemic inflammatory response syndrome) AND
* Strongly suspected or documented source of infection
* Not previously enrolled in the GAPPSS investigation

* Admitted to the PICU AND
* Age newborn (\>38 weeks EGA)-18 years AND
* Weight equal to or greater than 4 kg AND
* Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
* Parents speak English AND
* Severe respiratory dysfunction requiring invasive or non-invasive positive pressure mechanical ventilation support AND
* Positive PCR verifying a viral infection
* Not previously enrolled in the GAPPSS investigation

Exclusion Criteria

* Pre- or post-operative culture positive infection OR
* Not expected to survive the CICU stay OR
* Ward of the state OR
* Concurrent malignancy or autoimmune disorder

B. CSSS (Clinical Severe Sepsis Syndrome) group: systemic inflammation, in the presence of highly suspected or documented bacterial infection. Children with clinical severe sepsis, n = 40. In this group, the investigators will enroll children who are immunocompetent as well as children who are immunocompromised.

* PICU nosocomial primary infection accounting for the sepsis event
* Not expected to survive the PICU stay
* Ward of the state

C. Viral Infection group. Severe respiratory dysfunction in the presence of PCR -documented viral infection. Children with clinical severe viral sepsis, n=6. In this group, the investigators will enroll children who are immunocompetent as well as children who are immunocompromised.

* PICU nosocomial primary infection accounting for the sepsis event
* Not expected to survive the PICU stay
* Ward of the state

Minimum Eligible Age

38 Weeks

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No